Last reviewed · How we verify
NCT04784000
Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527
Phase 1 trial testing Period 1: AT-527 550 mg in Healthy Volunteer Study in 20 participants. Completed in 10 April 2021.
10 April 2021
Quick facts
| Lead sponsor | Atea Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 March 2021 |
| Primary completion | 10 April 2021 |
| Estimated completion | 10 April 2021 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Period 1: AT-527 550 mg — full drug profile →
- Period 2: carbamazepine — full drug profile →
- Period 3: AT-527 550 mg + carbamazepine — full drug profile →
- Period 3: AT-527 1100 mg + carbamazepine — full drug profile →
Conditions studied
- Healthy Volunteer Study — all drugs for Healthy Volunteer Study →
Sponsor
Atea Pharmaceuticals, Inc. — full company profile →
Who can join
Adults 18 to 65, any sex, with Healthy Volunteer Study. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will determine the effect of carbamazepine on the PK of AT-527 (RO7496998) in healthy adult subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04784000
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Volunteer Study
Currently open trials in the same condition.
- NCT06825364 — Near-InfraRed Spectroscopy of Auricular Stimulation · NA · recruiting
- NCT07021079 — Muscle Vibration as a Countermeasure Against Hypoactivity-induced · NA · recruiting
- NCT06945614 — Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation · Phase 1 · recruiting
Other Atea Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT07272889 — Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) · Phase 1 · completed
- NCT07007806 — Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir · Phase 1 · completed
- NCT06921941 — Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin · Phase 1 · completed
- NCT06356194 — Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir · Phase 1 · completed
- NCT06204679 — Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04784000 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Atea Pharmaceuticals, Inc.
- Last refreshed: 29 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04784000.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing